Knopp Neurosciences Inc., of Pittsburgh, named Cheryl Graham senior vice president of regulatory affairs and development strategy.

Lexicon Pharmaceuticals Inc., of The Woodlands, Texas, appointed Judith Swain to its board.

Lorus Therapeutics Inc., of Toronto, elected Denis Burger, Susan Koppy and Mark Vincent to its board.

MacroGenics Inc., of Rockville, Md., elected Jeffrey Buchalter chairman.

Magnisense, of Paris, appointed Sebastiene Quesney technical development manager.

Med BioGene Inc., of Vancouver, British Columbia, appointed Melanie Mahtani executive advisor for commercial development.

Medicure Inc., of Winnipeg, Manitoba, named Brian Best vice president of marketing.

MicroMed Cardiovascular Inc., of Houston, appointed T. Deanne Yartz chief financial officer.

Morria Biopharmaceuticals plc, of London, appointed Rosemary Mazanet interim CEO and appointed Johnson Lau and David Sidransky to its board.

Mpex Pharmaceuticals Inc., of San Diego, appointed Jeffery Loutit chief medical officer.

NanoBio Corp., of Ann Arbor, Mich., appointed Lyou-fu Ma senior vice president of development and regulatory affairs, Susan Ciotti director of formulation research and development and added Robert Hagan as senior manager of supply chain and Paula Robinson as clinical project manager.

Neopharm Inc., of Waukegan, Ill., appointed Shahid Ali executive vice president of research and development.

Nile Therapeutics Inc., of Berkeley, Calif., appointed Daron Evans chief financial officer and named Jennifer Hodge vice president of development.